2022
FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice.
Justet A, Ghanem M, Boghanim T, Hachem M, Vasarmidi E, Jaillet M, Vadel A, Joannes A, Mordant P, Bonniaud P, Kolb M, Ling L, Cazes A, Mal H, Mailleux A, Crestani B. FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice. American Journal Of Respiratory Cell And Molecular Biology 2022, 67: 173-187. PMID: 35549849, DOI: 10.1165/rcmb.2021-0246oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLung collagen contentLung fibrosisFGF19 concentrationsBAL fluidPulmonary fibrosisControl subjectsFibrosis markersMediator expressionFibrotic lung disordersPrimary human lung fibroblastsAlveolar type II cellsDecreased liver fibrosisInhibit lung fibrosisPlasma of patientsBim protein expressionInhibition of JNK phosphorylationCollagen contentType II cellsHuman lung fibroblastsAntifibrotic propertiesFibrotic phaseLung diseaseLung disordersLiver fibrosis
2020
Recent Advances in Molecular Basis of Lung Aging and Its Associated Diseases
Kang M. Recent Advances in Molecular Basis of Lung Aging and Its Associated Diseases. Tuberculosis And Respiratory Diseases 2020, 83: 107-115. PMID: 32185913, PMCID: PMC7105435, DOI: 10.4046/trd.2020.0003.Peer-Reviewed Original ResearchAging-related lung disordersLung disordersChronic obstructive pulmonary diseaseMajor unmet medical needObstructive pulmonary diseaseChronic lung disordersIdiopathic pulmonary fibrosisMolecular basisMolecular featuresBiological functionsUnmet medical needMolecular mechanismsCrucial risk factorMolecular understandingMolecular biologyBiologyPulmonary diseaseLung agingPulmonary fibrosisRisk factorsAdvanced agePulmonary medicineAssociated diseaseMedical needProgressive decline
2018
Human airway trypsin‐like protease exerts potent, antifibrotic action in pulmonary fibrosis
Menou A, Flajolet P, Duitman J, Justet A, Moog S, Jaillet M, Tabèze L, Solhonne B, Garnier M, Mal H, Mordant P, Castier Y, Cazes A, Sallenave J, Mailleux A, Crestani B. Human airway trypsin‐like protease exerts potent, antifibrotic action in pulmonary fibrosis. The FASEB Journal 2018, 32: 1250-1264. PMID: 29122847, DOI: 10.1096/fj.201700583r.Peer-Reviewed Original ResearchConceptsHuman airway trypsin-like proteaseIdiopathic pulmonary fibrosisPulmonary fibrosisAntifibrotic actionHAT expressionBleomycin-induced pulmonary fibrosis modelPrimary human pulmonary fibroblastsAberrant wound healing responseFibrotic lung disordersDestruction of lung parenchymaAttenuate lung injuryPulmonary fibrosis modelProstaglandin E2 pathwayHuman pulmonary fibroblastsWound healing responseBleomycin challengeLung injuryTrypsin-like proteaseExtracellular matrix depositionExcessive extracellular matrixLung disordersPulmonary fibroblastsFibrosis modelLung parenchymaDeposition of excessive extracellular matrix
2015
Epigenetics in idiopathic pulmonary fibrosis
Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochemistry And Cell Biology 2015, 93: 159-170. PMID: 25659821, DOI: 10.1139/bcb-2014-0126.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisChronic lung disordersLung disordersDNA sequencesFibroproliferative lung disordersTranslational epigenetic studiesIndividual DNA sequencesEpithelial wound repairVariable disease phenotypesPulmonary fibrosisChronic inflammationLung cancerInjurious stimuliHeritable changesEffective treatmentGene functionEpigenetic modificationsEpigenomic alterationsEpigenetic studiesCurrent experimental evidenceDisease paradigmWound repairDisease phenotypeDisordersEnvironmental changes
2011
Interstitial Lung Disease in Older Patients
Antin-Ozerkis D. Interstitial Lung Disease in Older Patients. Respiratory Medicine 2011, 201-226. DOI: 10.1007/978-1-60761-727-3_11.Peer-Reviewed Original ResearchInterstitial lung diseaseDiffuse parenchymal lung diseaseLung diseaseOlder patientsRespiratory statusTerm interstitial lung diseasePatient's respiratory statusParenchymal lung diseaseDetailed physical examinationYounger patientsPathologic featuresCareful historyPhysical examinationLung disordersMedical conditionsSpecific diagnosisPhysiologic studiesDiagnostic approachMultidisciplinary conferenceDiseasePatientsPathologic tissueHeterogeneous groupLaboratory dataCertain diseases
2010
Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis
Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Müller-Quernheim J. Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 540-548. PMID: 20442436, DOI: 10.1164/rccm.200909-1451oc.Peer-Reviewed Original ResearchConceptsVasoactive intestinal peptideRegulatory T cellsT cellsImmunoregulatory effectsImmunoregulatory roleLung disordersVIP treatmentCapacity of VIPChronic inflammatory lung disordersPeripheral regulatory T cellsTumor necrosis factor-alpha productionClinical phase II studyNecrosis factor-alpha productionConventional effector T cellsEpitheloid cell granulomasFatal organ dysfunctionPhase II studyEffector T cellsExaggerated immune responseChronic lung inflammationInflammatory lung disordersBronchoalveolar lavage fluidNew therapeutic principleImportant immunoregulatory roleActive diseaseChapter 3 Gender Differences in Pediatric Pulmonary Disease
Sheares B. Chapter 3 Gender Differences in Pediatric Pulmonary Disease. 2010, 35-50. DOI: 10.1016/b978-0-12-374271-1.00003-4.Peer-Reviewed Original ResearchPulmonary diseaseRespiratory diseasePediatric lung disordersCommon respiratory diseasesPediatric pulmonary diseaseNormal lung developmentGender-specific differencesPathophysiologic mechanismsLung disordersGender differencesHormonal differencesLung developmentRespiratory systemDiseasePrenatal developmentInfluence of genderAdolescent yearsMalesFemalesSocio-cultural factorsDifferencesMedical interestIncidenceDiagnosis
2007
Approaching the degradome in idiopathic pulmonary fibrosis
Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. The International Journal Of Biochemistry & Cell Biology 2007, 40: 1141-1155. PMID: 18207447, DOI: 10.1016/j.biocel.2007.11.020.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisIPF lungsProgressive fibrosisEpithelial injuryUnknown etiologyLung disordersBody of evidenceLung fibrogenesisLung parenchymaAbnormal remodelingExaggerated accumulationFibrosisSignificant upregulationExtracellular matrixLungCritical roleGene expression studiesFoci formationGlobal gene expression studiesFibrogenesisPathogenesisInjuryEtiologyParenchyma
2004
3 Gender-Specific Pulmonary Disease
Sheares B. 3 Gender-Specific Pulmonary Disease. 2004, 25-35. DOI: 10.1016/b978-012440905-7/50267-x.Peer-Reviewed Original ResearchRespiratory distress syndromeRespiratory diseasePulmonary diseasePediatric respiratory diseasesCommon respiratory diseasesGender-specific differencesAirway functionDistress syndromePremature infantsPathophysiologic mechanismsClinical manifestationsLung diseaseLung disordersLung growthSex-specific differencesHormonal differencesClinical arenaRespiratory systemDiseaseSex differencesAdolescent yearsGender differencesSociocultural factorsDifferencesInfants
2001
PULMONARY FUNCTION TESTS AT WORK
Sood A, Redlich C. PULMONARY FUNCTION TESTS AT WORK. Clinics In Chest Medicine 2001, 22: 783-793. PMID: 11787665, DOI: 10.1016/s0272-5231(05)70066-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung diseaseOccupational lung disordersPulmonary function testsManagement of patientsMethacholine challenge testingOccupational lung diseaseCareful occupational historySerial PFTsSuch patientsFunction testsLung disordersPopulation of workersClinical evaluationLung volumeOccupational exposurePEF recordingsRespiratory conditionsOccupational historyChallenge testingImportant causeDisability evaluationMedical screeningOccupational settingsPatientsDisease
1999
The Immunology and Prevention of Isocyanate Asthma: A Model for Low Molecular Weight Asthma
Redlich C, Cain H, Wisnewski A. The Immunology and Prevention of Isocyanate Asthma: A Model for Low Molecular Weight Asthma. Seminars In Respiratory And Critical Care Medicine 1999, 20: 591-599. DOI: 10.1055/s-2007-1009478.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
1995
Retinoic acid inhibition of transforming growth factor-beta-induced collagen production by human lung fibroblasts.
Redlich C, Delisser H, Elias J. Retinoic acid inhibition of transforming growth factor-beta-induced collagen production by human lung fibroblasts. American Journal Of Respiratory Cell And Molecular Biology 1995, 12: 287-295. PMID: 7873195, DOI: 10.1165/ajrcmb.12.3.7873195.Peer-Reviewed Original ResearchConceptsHuman lung fibroblastsRetinoic acidCollagen productionChronic inflammatory lung disordersDoses of RALung fibroblastsType IInhibitory effectInflammatory lung disordersTrans retinoic acidFibroblast collagen productionM retinoic acidLung disordersPotent immunomodulatorFibrotic responseRetinoid compoundsType III collagenBasal levelsSignificant inhibitionAcid inhibitionSignificant decreaseRetinoidsUnstimulated cellsPreincubationStimulation
1985
Sleep in Restrictive Lung Disorders
Kryger M. Sleep in Restrictive Lung Disorders. Clinics In Chest Medicine 1985, 6: 675-677. PMID: 3853479, DOI: 10.1016/s0272-5231(21)00404-4.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply